-
Patent Agency Ranking
公开(公告)号：US10279049B2
公开(公告)日：2019-05-07
申请号：US15587927
申请日：2017-05-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Qiang Cong , Sanjeev Gangwar , Vangipuram S. Rangan , Mei-Chen Sung
IPC: A61K39/395 , A61K47/68 , C07K16/28
Abstract: The drug component of an antibody-drug conjugate having a structure according to formula (II), where Ab, m, n, R1, R2, R3, R4, and R5 are as defined in the application, exhibits unexpectedly improved stability.
-
公开(公告)号：US09109008B2
公开(公告)日：2015-08-18
申请号：US14177498
申请日：2014-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Qiang Cong , Heng Cheng , Sanjeev Gangwar
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/48246 , A61K47/48415 , A61K47/48569 , A61K47/48592 , A61K47/48607 , A61K47/48615 , A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
Abstract translation: 其中R 1，R 2 R 3 a，R 3b，R 4，R 5，W和n如本文所定义的式（I）的调蛋白素化合物是可用于治疗癌症的抗有丝分裂剂，特别是当与靶向部分缀合时 。
-
公开(公告)号：US08980824B2
公开(公告)日：2015-03-17
申请号：US14177376
申请日：2014-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Qiang Cong , Heng Cheng , Sanjeev Gangwar
IPC: A61K38/00 , A61K39/00 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , C07K5/117 , A61K47/48 , C07K7/06 , C07K5/06 , C07K5/078
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/48246 , A61K47/48415 , A61K47/48569 , A61K47/48592 , A61K47/48607 , A61K47/48615 , A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
Abstract translation: 其中R 1，R 2，R 3a，R 3b，R 4，R 5，W和n如本文所定义的式（I）的调节素化合物是可用于治疗癌症的抗有丝分裂剂，特别是当与 靶向部分。
-
公开(公告)号：US09688721B2
公开(公告)日：2017-06-27
申请号：US15171592
申请日：2016-06-02
Applicant: Bristol-Myers Squibb Company
Inventor： Qiang Cong , Heng Cheng , Sanjeev Gangwar
IPC: A61K38/00 , C07K5/117 , A61K47/48 , C07K7/06 , C07K5/10 , A61K38/07 , C07K5/06 , C07K5/078 , A61K38/05 , C07K5/107
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/48246 , A61K47/48415 , A61K47/48569 , A61K47/48592 , A61K47/48607 , A61K47/48615 , A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
-
公开(公告)号：US09382289B2
公开(公告)日：2016-07-05
申请号：US14605549
申请日：2015-01-26
Applicant: Bristol-Myers Squibb Company
Inventor： Qiang Cong , Heng Cheng , Sanjeev Gangwar
IPC: A61K38/00 , C07K5/117 , A61K47/48 , C07K7/06 , C07K5/10 , A61K38/07 , C07K5/06 , C07K5/078 , A61K38/05 , C07K5/107
CPC classification number: C07K5/1024 , A61K38/05 , A61K38/07 , A61K47/48246 , A61K47/48415 , A61K47/48569 , A61K47/48592 , A61K47/48607 , A61K47/48615 , A61K47/48638 , A61K47/6811 , A61K47/6851 , A61K47/6857 , A61K47/6861 , A61K47/6863 , A61K47/6869 , C07K5/06 , C07K5/06139 , C07K5/06165 , C07K5/10 , C07K5/1016 , C07K7/06
Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
-
-
-
-
Search Results
5
records
(took 0.018 seconds)
